Journal of Clinical Oncology
Articles in this Issue
Dynamic regulation of CLDN18.2 expression during immunotherapy: Implications for biomarker-driven therapy in gastric cancer.
430 Background: Claudin 18.2 (CLDN18.2) has emerged as a promising therapeutic target in gastric cancer (GC), yet its biol...
Fruquintinib and pirfenidone in combination with anti-PD-1 antibody in pMMR/MSS metastatic colorectal carcinoma: A prospective, single-arm, phase Ib/II trial.
123 Background: The combination of fruquintinib and anti-PD-1 has synergistic anti-tumor effects. However, liver metastase...
Real-world treatment patterns and outcomes in metastatic squamous cell carcinoma of the anal canal (SCAC): A retrospective electronic health record study.
5 Background: SCAC is a rare malignancy with rising incidence and mortality; in the metastatic setting, disease burden, tr...
Consensus molecular subtypes and divergent genomic landscapes with clinical implications in biliary tract cancers.
600 Background: Biliary tract cancers (BTC), including cholangiocarcinomas and gallbladder adenocarcinomas, remain poorly...
Pancreastatin as a predictive biomarker for outcomes with peptide receptor radionuclide therapy in patients with neuroendocrine tumors: A retrospective analysis.
644 Background: Serum pancreastatin, a cleave product of chromogranin A, has shown promise as a prognostic and predictive...
Clinicopathologic features and overall survival of patients with early-onset colorectal cancer in a South African cohort study.
58 Background: The incidence of early-onset colorectal cancer (EOCRC) has increased across sub-Saharan Africa, but data de...
Association of uncommon <i>DPYD</i> polymorphisms with severe fluoropyrimidine toxicity.
112 Background: Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity, especially in patients with dihydr...
<i>DPYD</i> genotype-guided dose personalization for fluoropyrimidine prescribing in Australia: GeneScreen 5-FU trial.
TPS250 Background: Fluoropyrimidine (FP) is a common chemotherapy class used across multiple tumor streams, including firs...
A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.
TPS471 Background: Definitive chemoradiotherapy is one of the standard treatments for unresectable locally advanced esopha...
A phase II trial of perioperative tumor treating fields (NovoTTF-200T[P]) combined with gemcitabine and nab-paclitaxel in resectable pancreatic adenocarcinoma: Big Ten Cancer Research Consortium (BTCRC-GI21-500).
TPS797 Background: Resectable pancreatic ductal adenocarcinoma (R-PDA) continues to be associated with high recurrence and...
Comparative effectiveness of oxaliplatin or irinotecan rechallenge vs standard third-line therapies in patients with metastatic colorectal cancer.
79 Background: Following first- (1L) and second-line (2L) treatment including a fluoropyrimidine, oxaliplatin, irinotecan,...
Genomic characteristics, clinical profiling, and outcomes of advanced pancreatic ductal adenocarcinoma (PDAC) with <i>MTAP</i> -deletion ( <i>MTAP</i> -del): Analyses from a multimodal real-world dataset.
682 Background: Homozygous MTAP -del is found in 10–15% of all cancers. Patients (...
Incidence trends and misclassification patterns of hepatocholangiocarcinoma: A SEER database analysis.
603 Background: Hepatocholangiocarcinoma (H-ChC), or combined hepatocellular–cholangiocarcinoma, is a rare primary liver m...
A novel self-controlled electroacupuncture helmet for chemotherapy-induced cognitive impairment: Results from a prospective randomized trial.
337 Background: Chemotherapy-induced cognitive impairment (CICI) affects 30% of cancer patients, with limited treatment op...
Longitudinal clinical validation of the Northstar response using methylated ctDNA as a dynamic treatment response biomarker in advanced stage gastrointestinal (GI) cancers.
237 Background: Radiographs remain the cornerstone of tumor response evaluation for managing advanced GI cancers. However,...
A head-to-head comparison of GPT-based prognostic predictions and oncologists in gastrointestinal cancers.
808 Background: Patients and families want to know their likely survival times but oncologists have trouble making estimat...
Perioperative chemotherapy versus preoperative chemoradiation therapy in gastroesophageal adenocarcinomas: Real-life data from a Canadian academic oncology center.
405 Background: Perioperative chemotherapy is a standard of care (SOC) for patients with resectable gastroesophageal junct...
Relative survival at 1, 3, 5, and 10 years by race/ethnicity in colorectal cancer: A SEER-based analysis.
50 Background: Colorectal cancer remains a leading cause of cancer death in the United States. Population-based estimates...
An update on the impact of COVID-19 on colorectal cancer screening using Medicare claims data.
87 Background: In March 2020, the Centers for Medicare & Medicaid Services (CMS) recommended delaying non-urgent proce...
Response rate of MSI-high/dMMR upper and lower GI cancers to neoadjuvant immunotherapy: A systematic review.
403 Background: The success of immunotherapy to treat metastatic microsatellite instability high (MSI-h)/deficient mismatc...
The primary results of a randomized phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus FTD/TPI for previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma (RETRIEVE study, WJOG 15822G).
357 Background: Trifluridine/tipiracil (FTD/TPI) has demonstrated survival benefit in the third- or later-line treatment f...
Barriers to timely diagnosis of early-onset colorectal cancer: A systematic review and qualitative analysis.
42 Background: Early-onset colorectal cancer (EOCRC), defined as a diagnosis of colorectal cancer in a patient <50 year...
A feasibility analysis to align fit-for-purpose real-world (RW) data to emulate the AZUR-1 single-arm clinical trial in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer (RC).
70 Background: AZUR-1, a clinical trial (NCT05723562) evaluating dostarlimab for pts with dMMR/MSI-H stage II/III RC, has a single-arm design...
PROACTIF: Final results from the largest prospective real-world study of 1196 primary liver cancer patients (PLC) treated with yttrium-90 (Y90) glass transarterial radioembolization (TARE).
504 Background: This study evaluated the effectiveness, quality-of-life, safety, and dosimetry of Y90 glass microspheres f...
Liquid biopsy to reveal colorectal cancer molecular subtype information from ctDNA epigenetics.
238 Background: Consensus molecular subtypes (CMS1-4) have shown prognostic value in colorectal cancer (CRC) and may predi...